Skip to content
Biodatica
Start free

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

LA JOLLA, CA

Oncologysmall moleculePhase II
Compare Sign in to watch

What changed

Phase II trial registered: A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

3w agoTrial registeredJun 22, 2026Source filing (opens the source filing in a new tab)

Momentum

88no change

Momentum 88 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,323 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $772k · non-dilutive

    Jun 1, 2026

    UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, DONG-ER · NCI · award ends May 31, 2029 · Identification of small molecule activators of Type I interferon signaling for cancer treatment

    NIH RePORTER · NIH RePORTER 11297664 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Mar 15, 2026

    ICU, Critical Illness, Adult · NOT_YET_RECRUITING · sponsor: The First Hospital of Jilin University · Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients

    ClinicalTrials.gov · NCT07414160 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Nov 12, 2024

    Moyamoya Disease · RECRUITING · sponsor: Beijing Tiantan Hospital · Family-Based Moyamoya Susceptibility and Early Detection

    ClinicalTrials.gov · NCT07517354 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Apr 27, 2023

    Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer · COMPLETED · sponsor: Sun Yat-sen University · A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

    ClinicalTrials.gov · NCT05742750 (opens the source filing in a new tab)

  5. Grant

    R01 · $646k · non-dilutive

    Mar 22, 2023

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COMMISSO, COSIMO · NCI · award ends Feb 28, 2027 · Discovery of Novel Inhibitors Targeting trans-Golgi Network Acidification in Pancreatic Cancer

    NIH RePORTER · NIH RePORTER 11283957 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources